ally mild to moderate. Less than 4% of subjects reported having severe events in any of the vaccine or age groups, and no vaccine-related serious adverse events were reported (for details, see the Supplementary Appendix, available with the full text of this letter at NEJM.org). By day 22, all three vaccine regimens had elicited increases in HI titers in the two age groups (Fig. 1) . Rates of seroconversion were greater than 70% in all age and vaccine groups. After a single dose of vaccine, all three vaccine regimens met the CBER criterion for the HI antibody titer among subjects 9 to 17 years of age, but only the 7.5-μg dose of vaccine with adjuvant met this criterion among children 3 to 8 years of age. These preliminary data support the use of one 15-μg dose of 2009 H1N1 vaccine without adjuvant in children between the ages of 9 and 17 years. However, in children 3 to 8 years of age, only the 7.5-μg dose of 2009 H1N1 vaccine with adjuvant met both the immunogenicity criteria after one dose, and the criterion for the HI antibody titer was not met by either one or two 15-μg doses without adjuvant. The use of adjuvant may provide a rapid immune response at a lower hemagglutinin dose than that required in vaccine without adjuvant. This may increase the availability of vaccine for rapid immunization in young children, an age group that is at substantial risk for hospitalization associated with influenza. Adriano Arguedas, M.D. Carolina Soley, M.D.
